37.4% difference in ALSFRS-R in patients treated with PrimeC vs. placebo, demonstrating PrimeC’s potential to provide a meaningful clinical benefit to people living with ALS.

$nrsn Breaking News!

We are pleased to share that the pre-defined Per Protocol analysis of the top-line Phase 2b PARADIGM trial results revealed a statistically significant 37.4% difference in ALSFRS-R in patients treated with PrimeC vs. placebo, demonstrating PrimeC’s potential…

Please help us reach as many as possible - share this message with your loved ones. Together, we can make a difference. 🩵 #ALS

$nrsn 'the results exceeded our expectations, as PrimeC increased the survival rate to the level of the healthy control and that got us very excited.'
Dr. Justin Ichida

$nrsn 'These results further bolster our confidence that PrimeC may offer a much-needed therapy for this debilitating disease which is ALS. We are proud that PrimeC is recognized as a leading ALS drug candidate by the top medical institutions in the world'
Alon Ben-Noon

In the next few days I'll be discussing $BCLI Adcomm and why the path of $NRSN is not only distinct but also exceptionally unique. 🧠 Mark your calendars for December when we unveil the Paradigm results. Stay tuned!

Our Investor webinar will focus on NeuroSense’s Phase 2b ALS clinical trial design, endpoints analysis and progress, Alzheimer Disease Phase 2 study design, endpoints and progress, as well as upcoming catalysts.
Register in advance for this webinar:
lnkd.in/eZYxSNW4

finance.yahoo.com/news/neurosens…

linkedin.com/posts/alonbn_a…

linkedin.com/posts/alonbn_a…

🧠💡 Exploring the Mind-Body Connection: Elon Musk's mission to merge tech and neuroscience is igniting hope for Locked-in Patients.
By pushing boundaries, we're on the brink of innovative breakthroughs that could transform treatment and slow down the degeneration itself.

In the realm of medical advancements, there's a pressing call for progress in the treatment of ALS.
With its impact on individuals and their families, finding an effective therapy isn't just a medical goal – it's a matter of compassion and hope.

$nrsn Announces Second Quarter 2023 Financial Results and Provides Business Update

Main points:

+ Topline results expected in Q-4 2023
+ Cash runway beyond topline clinical study readouts, into Q-2 2024

finance.yahoo.com/news/neurosens…

$NRSN Breakfast Club - Proud of the team and the great achievements. Anticipating the near future milestones...

This is a brilliant collab using NeuroSense Therapeutics’s PARADIGM data and Biogen’s NfL data to advance NfL as an #ALS biomarker.

$nrsn
Exciting major ALS discovery by the Justin Ichida lab at USC, in an independent, non-sponsored research.
PrimeC Performed Favorably in comparison to approved and experimental ALS therapies.
courtesy of Dr. Justin Ichida

Thanks for leading the The The ALS Association with a great passion and care.
Brainstorming on how to expedite the development of effective therapies and assuring All patients have access, is a mutual goal and the outcome may affect so many lives.
Looking forward to advancing this.

Announcing Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US

prnewswire.com/news-releases/…

$nrsn - This is a great milestone, achieved thanks to our amazing collaborators and the amazing team at NeuroSense:

finance.yahoo.com/news/neurosens…

Wishing our friends at Amylyx good luck today at the FDA AdCom

youtu.be/6PMOyqd6WfA